Therapies

March 19, 2019

Axcan has completed its acquisition of Eurand N.V., a global specialty pharmaceutical company with operating units in the United States and Europe. In a February 11 letter, Axcan President and CEO Frank Verwiel explained how the merger will affect its customers: Dear Customer: We are pleased to...

Cystic Fibrosis at the Presidential State of the Union VIA SCIENCEMAG.ORG

by BEF

CF Community, CF News, Policy, Research, Therapies

March 19, 2019

"Science gets its moment in Obama's 2015 State of the Union" VIA SCIENCEMAG.ORG By David Malakoff Science rarely makes a major appearance in the President’s annual State of the Union address. Tonight’s speech by President Barack Obama maintained that tradition – but he did take a few moments...

With Resurgence in Polymyxin Use, CHMP Revises Label via Medscape.com

by BEF

CF News, Policy, Therapies

March 19, 2019

SOURCE The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended revisions to the product information for antibiotics known as polymyxins (colistin or colistimethate sodium) for the treatment of serious infections that are resistant to standard antibiotics. Polymyxins, first introduced in the 1960s,...

Therapies

Axcan Pharma CEO Explains Impact of Axcan-Eurand Merger

Cystic Fibrosis at the Presidential State of the Union VIA SCIENCEMAG.ORG

With Resurgence in Polymyxin Use, CHMP Revises Label via Medscape.com

Never miss an update. Subscribe to our emails!